Norepinephrine-stimulated HSCs secrete sFRP1 to promote HCC progression following chronic stress via augmentation of a Wnt16B/β-catenin positive feedback loop
Journal of Experimental & Clinical Cancer Research volume 39, Article number: 64 (2020)
Sustained adrenergic signaling secondary to chronic stress promotes cancer progression; however, the underlying mechanisms for this phenomenon remain unclear. Hepatocellular carcinoma (HCC) frequently develops within fibrotic livers rich in activated hepatic stellate cells (HSCs). Here, we examined whether the stress hormone norepinephrine (NE) could accelerate HCC progression by modulating HSCs activities.
HCC cells were exposed to conditioned medium (CM) from NE-stimulated HSCs. The changes in cell migration and invasion, epithelial-mesenchymal transition, parameters of cell proliferation, and levels of cancer stem cell markers were analyzed. Moreover, the in vivo tumor progression of HCC cells inoculated with HSCs was studied in nude mice subjected to chronic restraint stress.
CM from NE-treated HSCs significantly promoted cell migration and invasion, epithelial-mesenchymal transition (EMT), and expression of cell proliferation-related genes and cancer stem cell markers in HCC cells. These pro-tumoral effects were markedly reduced by depleting secreted frizzled related protein 1 (sFRP1) in CM. The pro-tumoral functions of sFRP1 were dependent on β-catenin activation, and sFRP1 augmented the binding of Wnt16B to its receptor FZD7, resulting in enhanced β-catenin activity. Additionally, sFRP1 enhanced Wnt16B expression, reinforcing an autocrine feedback loop of Wnt16B/β-catenin signaling. The expression of sFRP1 in HSCs promoted HCC progression in an in vivo model under chronic restraint stress, which was largely attenuated by sFRP1 knockdown.
We identify a new mechanism by which chronic stress promotes HCC progression. In this model, NE activates HSCs to secrete sFRP1, which cooperates with a Wnt16B/β-catenin positive feedback loop. Our findings have therapeutic implications for the treatment of chronic stress-promoted HCC progression.
Emerging evidence suggests that chronic stress in patients, including fear, anxiety, and depression, can promote cancer progression by inducing overactivity of the sympathetic nervous system (SNS) [1,2,3,4]. Chronic stress has been shown to increase the production of stress hormones such as norepinephrine (NE) and epinephrine from the SNS, enhancing tumor growth, invasion, and metastases in multiple malignancies [5,6,7]. However, the molecular mechanisms underlying the effects of chronic stress on cancer promotion are not fully understood.
Hepatocellular carcinoma (HCC) ranks fourth among cancer-related deaths worldwide . HCC often arises on a background of inflamed or fibrotic livers rich in activated hepatic stellate cells (HSCs) [9,10,11]. As major sources of extracellular matrix (ECM) deposition, activated HSCs can profoundly alter the tumor microenvironment [11,12,13], and interactions between HCC and activated HSCs greatly influence HCC onset and progression [14,15,16,17]. In addition, it has been reported that hyperactive SNS contributes to the stress-induced aggravation of many liver diseases through its catecholamine neurotransmitters (including NE) [2, 18, 19]. Further, several neuronal genes were found to be highly expressed in HSCs, including adrenergic receptors [20,21,22,23,24,25,26]. This prompted us to hypothesize that chronic stress could affect HCC progression through stress hormone-modulating HSC activities.
In this study, we showed the crosstalk between chronic stress and HCC progression through NE-mediated activation of HSCs. Our observations included the following: (i) conditioned medium from NE-stimulated HSCs significantly enhanced the malignant phenotype of HCC cells; (ii) secreted frizzled-related protein 1 (sFRP1), a regulator of Wnt signaling, played a key role in the stress response of HSCs to NE and mediated the pro-tumoral effects of HSCs on HCC cells; (iii) sFRP1 enhanced Wnt16B expression to augment an autocrine feedback loop of Wnt16B/β-catenin signaling in HCC cells; (iv) expression of sFRP1 in HSCs accelerated HCC progression in an in vivo model under chronic restraint stress, which was significantly thwarted by the knockdown sFRP1. This study has therapeutic implications for the treatment of chronic stress-driven HCC progression.
Materials and methods
Cell lines and culture conditions
The human liver cell L02 (Cell Bank of the Chinese Academy of Sciences, Shanghai, China), human HCC cell lines PLC/PRF/5, HepG2 and Hep3B (ATCC, USA), SMMC7721 (Cell Bank of the Chinese Academy of Sciences, Shanghai, China), MHCC97H and HCCLM3 (Liver Cancer Institute, Fudan University, Shanghai, China), and Huh7 (Japanese Cancer Research Resources Bank) were propagated in the corresponding culture medium RPMI-1640 or Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (Invitrogen). Human hepatic stellate cell line LX-2 (a gift from SL. Friedman, Mount Sinai, New York) were grown in DMEM containing 2% FBS. Primary human hepatic stellate cells (pHSCs) (ScienCell, USA) were maintained in the provided complete stellate cell medium. All cell cultures were conducted at 37 °C in a thermostatic incubator containing 5% CO2.
Norepinephrine (NE) treatment
For NE treatments, LX-2 cells were seeded in 6-well plates (2 × 105 cells/well) (Corning Inc., USA) for 8 h to allow the cells to adherent, and then treated with increasing concentrations of NE (0.1, 1, 5 and 10 μM) (Sigma-Aldrich Co., St. Louis, MO) for 24 h.
Conditioned media (CM) collected from NE-treated HSCs were used to cultivate HCC cells. In brief, LX2 cells or sRFP1 knockdown LX2 cells (LX-2shRNA sFRP1) were treated with 10 μM NE for 24 h. The next day, the medium was exchanged with fresh DMEM supplemented with 2% FBS without NE, and the cells were cultured for another 24 h. The supernatant of cells was harvested, filtered and centrifuged with 3000 rpm for 15 min to remove debris. For individual experiments, HCCs were incubated with CM collected from NE-treated HSCs.
Transfection of Lentiviral vectors with shRNA for sFRP1
LX2 cells with stable sFRP1 knockdown were generated using lentivirus-mediated knockdown of sFRP1. Lentiviral vectors encoding shRNA targeting sFRP1 or scramble (negative control) were purchased from the GENECHEM gene company, Shanghai, China. LX2 cells were transfected by lentivirus particles (multiplicity of infections, MOI =5) and then selected in culture medium with 2 μg/ml puromycin. The efficiency of gene silencing was assayed by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and Western blot.
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted from the cells or tissues using TRIzol reagent (Invitrogen, USA), Then, synthesis of cDNA reaction was carried out with 2 μg of total RNA using a PrimeScript RT Reagent Kit (Takara, Japan) following the manufacturer’s instructions. Subsequently, PCR amplification was done on cDNA using Maxinma SYBR Green qPCR Master Mix (Thermo Scientific). Quantification of target genes was performed with the 2−ΔΔCt method using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or β-actin for normalization. Melting curve analysis was used to check the specificity of PCR products. The used primers are listed in Table S1 (Additional file 1: Table S1).
Briefly, total proteins were extracted using RIPA (Radio-Immunoprecipitation Assay) lysis buffer containing 1 mM PMSF (Phenylmethanesulfonyl fluoride) (Beyotime, Beyotime Institute of Biotechnology, Shanghai, China) and 10% PhosSTOP phosphatase inhibitor Cocktail (Roche), and then resolved by electrophoresis through a 10% SDS-PAGE. The amount of separated proteins (20 μg per lane) was transferred onto 0.45 μM PVDF membranes (Millipore, USA) and incubated with primary antibody against α1A-adrenergic receptor (1:1000, Abcam), Collagen I (1:1000, Abcam), α-SMA (1:300, Abcam), α-AMPK (1:1000, CST, Cell Signal Technology), p- αAMPK (1:1000, CST), GSK-3β (1:1000, CST), p-GSK-3β (1:1000, Tyr 216) (Abcam), Cyclin D1 (1:10000, Abcam), c-Myc (1:10000, Abcam), Nanog (1:2000, CST), N-Cadherin(1:1000, Abcam), E-Cadherin(1:1000, Abcam), Vimentin (1:1000, Abcam), Snail (1:1000, Abcam), β-catenin (1:1000, CST), sFRP1 (1:1000, Abcam), Wnt 16B (1:1000, Bioss) or GAPDH (1:1000, Beyotime) and the corresponding HRP-conjugated secondary antibody (PeproTech). Protein band was developed using Ncm-ECL Ultra (New Cell & Molecular Biotech Co., Ltd., China).
Cell proliferation assay
Cell proliferation was measured using the Cell Counting Kit-8 assay (CCK-8, Yeasen, Shanghai, China). Briefly, cells were seeded into 96-well plates (1 × 103 cells /well) and cultured for the indicated time periods. Then, 10 μl of CCK-8 reagent was added into each well for 1 h at 37 °C. The absorbance was measured using a Multiskan spectrophotometer at a wavelength of 450 nm.
After fixed with 4% paraformaldehyde (Sangon, Shanghai, China), incubated with 0.3% Triton X-100 (Sangon, Shanghai, China) and blocked with 5% BSA (Sangon, Shanghai, China), the cells were incubated with primary antibody at 4 °C overnight, followed by incubation with the appropriate secondary antibody (Thermo Scientific). The nuclei were counterstained with 4, 6-diamidino-2-phenylindole (DAPI) (Yeasen, Shanghai, China). The intensity of fluorescence was detected using a confocal laser scanning microscopy (LSM510, Zeiss, Germany).
Migration and invasion assays
For migration analyzed by wound-healing assay, the cell monolayer was mechanically disrupted to produce a linear wound using a sterile 200 μl pipette tip. The distance migrated by cells was measured using a microscope equipped with an ocular micrometer. For invasion assay, 1 × 105 cells suspended in serum-free medium were seeded into the upper chamber coated with Matrigel (BD Biosciences, USA) in 24-well transwell plates (8-μm pore size, Corning, NY, USA), and 600 μl DMEM with 10% FBS was added into the lower chamber. After incubation for an indicated time points, the invading cells on the outer side of the upper chamber membrane were fixed with 4% paraformaldehyde, stained with crystal violet and counted under a light microscopy.
Flow cytometric analysis
For analysis of apoptosis using Alexa Fluor 488 Annexin V Kit (Invitrogen), the cells (1 × 106 cells/ml) were harvested, washed with PBS and centrifuged at 1000 rpm for 5 min. Then, the cell pellet was re-suspended in the annexin-binding buffer, incubated with annexin V and PI working solution for 15 min at room temperature. Cell apoptosis was determined using FACS caliber Flow cytometer (BD Biosciences, San Jose, CA, USA) and FlowJo software (Tree Star, San Carlos, CA).
The mRNA expression profiles were generated using Affymetrix GeneChip arrays (Affymetrix, Santa Clara, CA, US) according to the manufacturer’s instructions, as described previously .
Enzyme-linked Immunosorbent assay (ELISA)
The sFRP1 level in conditioned media collected from cells treated with NE was measured by an ELISA kit (R&D Systems, Wiesbaden, Germany) following the manufacturer’s instructions. For NE, tissue was homogenized in 0.01 M HCl at 10% volume (ml) by tissue weight. NE in serum and tissue was quantified by ELISA (Elabscience, E-EL-0047c, China) according to the manufacturer’s protocol, as described previously .
α-AMPK kinase blocking assay
For blocking experiments, LX2 cells were pre-incubated with Dorsomorphin (200 nM, 1 μM or 5 μM) (α-AMPK inhibitor, Selleck Chemicals, China) for 2 h prior to exposure to NE (10 μM) for another 4 h or 24 h.
Inhibition of GSK-3β kinase and β-catenin
HCC cells were pre-treated with GSK-3β inhibitor CHIR-99021 (10 μM) or β-catenin inhibitor XAV-939 (10 μM) (Selleck Chemicals, China) for 2 h, followed by the treatment of NE (10 μM) for another 3 h or 24 h.
To identify sFRP1-targeted molecules, co-immunoprecipitation was conducted as previously described. Briefly, HCC cells were lysed in immunoprecipitation buffer supplemented with a protease inhibitor for 2 h at 4 °C. The sample was centrifuged at 12,000 x g for 15 min, and the protein concentration was determined using the Bradford method (Beyotime, Beyotime Institute of Biotechnology, Shanghai, China). Precleared lysates with equivalent amounts of protein were incubated with a primary antibody overnight at 4 °C. Then, protein A- and G-Sepharose beads (Pierce Biotechnology, Rockford, IL, USA) were added to the immunoprecipitation (IP) mixture for 2 h. After that, the precleared lysate was incubated with a specific antibody coupled to protein A/G-agarose beads for 2 h at 4 °C. The precipitates were washed four times with immunoprecipitation buffer, resolved by 10% SDS-PAG, detected by western blot with specific antibody and visualized by enhanced chemiluminescence.
Wnt16B promoter analysis
HCC cells were transfected (riboFECT™ CP Reagent, Guangzhou RiboBio Co., Ltd) with a plasmid containing a full-length sequence of Wnt16B promoter (2000 bp upstream of transcription start site) and subsequently assayed for luciferase reporter gene expression (Promega), as described previously .
Immunohistochemistry was performed using the EnVision two-step Visualization System (GeneTech, Shanghai, China). Briefly, tumor specimens were removed, fixed in 10% neutral formalin and embedded with paraffin, and sliced into 5 mm thick sections. Sections were deparaffinized with xylene, followed by rehydration with a graduated series of ethanol, blocking endogenous peroxides with 3% H2O2, antigen-retrieval with microwave, blocking non-specific antibody binding. Slides were next incubated with primary antibodies against Cyclin D1 (1:50, Abcam), N-Cadherin(1:100, Abcam), E-Cadherin (1:100, Abcam), β-catenin (1:100, CST), sFRP1 (1:50, Abcam), overnight at 4 °C, followed by incubation with the secondary antibodies the next day, and visualized with 3,3-diaminobenzidine (DAB) as a chromogen. The slides were counterstained with hematoxylin.
All animal experiments were approved by the Ethical Committee on Animal Experiments of Animal Care Committee of Zhongshan Hospital of Fudan University, Shanghai, China and carried out according to the Shanghai Medical Experimental Animal Care Commission Guidelines. All Male BALB/c nude mice (4–6 weeks old and weighing 18–20 g) were purchased from SLAC Laboratory Animal Co., Ltd., Shanghai, China and housed in a pathogen-free condition, and all efforts were made to minimize animal suffering. In one experiment, mice were injected subcutaneously with a cell suspension containing 3× 107 Huh7 cells with or without 1× 107 LX-2 cells into the upper right flank portion of each mouse. After 5 days of tumor inoculation, mice were assigned to four groups: (a) Huh7 control group (n = 5); (b) Huh7 + daily stress group (n = 5); (c) Huh7/LX2 cells control group (n = 5); (d) Huh7/LX2 cells + daily stress group (n = 5). In the chronic stress, the mouse is restrained in a movement-restricted space using an acrylic cylindrical animal restrainer, which restricts the movement of the limbs with unlimited breathing. After restraint for 2 h, the mice were returned to their home cages and allowed access to food and water. The mice were subjected to daily restraint stress for 3 weeks as described previously . In the second experiment, cell suspensions containing 3× 107 Huh7 cells with 1× 107 sFRP1 shRNA LX-2 (LX-2shRNA sFRP1) or scramble shRNA LX-2 (LX-2shRNA NC) cells were injected subcutaneously into mice (n = 5 for each group). After 1 week of inoculation, mice were subjected to chronic stress for 3 weeks as described above. The length and width of the tumors were measured twice per week, and the tumor volume was calculated according to the formula: (length × width2)/2. After 1 month, mice were sacrificed, and tumors, livers, and lungs were harvested, fixed with 10% formalin or frozen in liquid nitrogen for the following analyses.
Ethical approval from the Zhongshan Hospital of Fudan University (Shanghai, China) Research Ethics Committee and patient written informed consents were obtained from each patient. HCC and matched nontumor liver tissues were collected from 26 patients who underwent curative resection at the Liver Cancer Institute, Zhongshan Hospital of Fudan University (Shanghai, China) in 2015. The pathologic diagnosis of HCC was confirmed. Clinicopathological information was retrieved from the medical records.
Data were expressed as means ± standard deviation (SD) from three independent experiments. All statistical analyses were performed using the GraphPad Prism Software (GraphPad Software, San Diego, CA). The unpaired Student’s t test, one-way analysis of variance (ANOVA) or Fisher’s exact test was conducted for comparison between groups wherever appropriate. All statistical tests were two-sided and a P < 0.05 was considered statistically significant.
NE is capable of activating HSCs via the α1A-ADR
The expression of adrenergic receptors (ADRs) was screened among HSCs (LX2 cells, p-HSC), liver cell line L02, and HCC cells (PLC/PRF/5, HepG2, Hep3B, Huh7 SMMC7721, MHCC97H, and HCCLM3). Compared with the varied expressions of α1B-, α1D-, β1-, β2- and β3-ADR in HSCs, liver cell line L02, and HCC cells (Additional file 2: Fig. S1), α1A-ADR mRNA expression was significantly upregulated in HSCs (Fig. 1a). Western blot analysis also confirmed the clear upregulation of α1A-ADR protein in HSCs (Fig. 1b). Positive immunofluorescence staining for α1A-ADR was observed in LX2 cells (Fig. 1c). NE treatment activated HSCs, as indicated by increased mRNA and protein expression of α-SMA and COL1A1 (primary signs of HSC activation), and enhanced cell proliferation (Additional file 3: Fig. S2). But, NE at the same concentrations as used for HSCs did not increase the proliferation of the HCC cells (Additional file 3: Fig. S2). More importantly, nonselective and selective α1-ADR antagonists (prazosin and 5-methylurapidi) efficiently suppressed NE-dependent HSC activation, as shown by reduced α-SMA and COL1A1 expression, reduced cell proliferation, and increased cell apoptosis in LX2 cells (Fig. 1d, e, f, g). In accordance with these changes, the α1-ADR antagonists significantly suppressed NE-induced cyclin D1 expression and remarkably increased the levels of cleaved caspase-3 (Fig. 1h). These results suggest that the stress hormone NE stimulates HSC activation through α1A-ADR signaling.
The pro-tumoral effects of CM from NE-stimulated HSCs on the malignant characteristics of HCC cells is mediated by sFRP1
Compared with CM from NE-untreated LX2 cells (Control), CM from NE-treated LX2 cells significantly enhanced the migration and invasion of HCC cells in vitro (Fig. 2a; Additional file 4: Fig. S3). In parallel with the phenotypic changes, epithelial-mesenchymal transition (EMT) was indicated by a decrease of E-cadherin expression and increases of N-cadherin, vimentin and snail expressions. (Fig. 2b; Additional file 4: Fig. S3). In addition to EMT activation, β-catenin, proliferation-related genes c-Myc and cyclin D1, and cancer stem cell marker Nanog were markedly upregulated in HCC cells exposed to CM from NE-treated LX2 (Fig. 2b; Additional file 4: Fig. S3). To determine which secreted protein was responsible for these pro-tumoral effects in NE-treated LX2-cells CM, we performed gene expression profiles of NE-treated versus vehicle-treated LX-2 cells. A total of 31 differentially expressed genes that might act as paracrine signals from LX2 cells to HCC cells were identified (Additional file 5: Table S2). Of these, sFRP1, a regulator of the Wnt signaling [29,30,31], was selected based on the above finding that β-catenin was significantly increased after HCC cells exposed to CM from NE-treated LX2 (Fig. 2b). The levels of sFRP1 mRNA and protein expression were remarkably increased after HSCs (LX-2, p-HSC) were exposed to NE (Fig. 2c). By contrast, there was no significant difference of sFRP1 expression between NE-untreated and NE-treated HCC cells (Additional file 6: Fig. S4). In addition, compared with other sFRP family members (sFRP2, sFRP3, sFRP4, sFRP5), sFRP1 mRNA expression was substantially upregulated by NE in a dose-dependent manner in LX2 cells (Additional file 6: Fig. S4). Although sFRP2 was significantly upregulated in NE-treated LX2 cells (Additional file 6: Fig. S4), the extent of sFRP1 increase in NE-treated LX2 cells was significantly higher than that of sFRP2. Notably, nonselective and selective α1-ADR antagonists (prazosin and 5-methylurapidi) significantly decreased the expression of sFRP1 in NE-treated LX2 cells detected by ELISA and western blot, whereas β-ADR antagonist propranolol did not reduce the expression of sFRP1 in NE-treated LX2 cells (Fig. 2d; Additional file 6: Fig. S4), suggesting that NE stimulates sFRP1 secretion from HSCs through α1A-ADR signaling. Recent research suggests that α1-ADR stimulation enhances the activity of AMPK , Additionally, an AMPK inhibitor (dorsomorphin) significantly decreased the expression of sFRP1 in NE-treated LX2 cells (Fig. 2d). These results indicate that sFRP1 secretion form NE-treated HSCs is through the activation of α1A-ADR/AMPK signaling.
To further define the roles of sFRP1 in the NE-stimulated HSC CM promotion of malignant phenotypes of HCC cells, we transfected LX-2 cells with a sFRP1-shRNA lentivirus (LX-2shRNA sFRP1) or a scramble-shRNA lentivirus (negative control, LX-2shRNA NC). The efficiency of gene silencing was confirmed (Additional file 7: Fig. S5). CM from NE-treated LX-2shRNA NC and LX-2shRNA sFRP1 cells were collected to culture with HCC cells (Huh7, MHCC 97H). Compared with CM from NE-treated LX-2shRNA NC, CM from NE-treated LX-2shRNA sFRP1 showed a significant decrease of invasion and migration of HCC cells in vitro (Fig. 2e; Additional file 7: Fig. S5). Consistently, EMT was significantly attenuated in HCC cells co-cultured with NE-treated LX-2shRNA sFRP1 versus NE-treated LX-2shRNA NC CM, evidenced by the higher E-cadherin expression and lower N-cadherin, Vimentin, and Snail expression (Fig. 2f; Additional file 7: Fig. S5). In addition, β-catenin, the proliferation-related gene cyclin D1 and cancer stem cell marker Nanog were markedly reduced in HCC cells exposed to CM from NE-treated LX-2shRNA sFRP1 compared with those cultured with CM from NE-treated LX-2shRNA NC (Fig. 2f; Additional file 7: Fig. S5). It has been reported that sFRP-1 regulates Wnt/β-catenin signaling [29, 33]. Western blot and immunofluorescence assays showed that β-catenin expression and its nuclear translocation were significantly decreased when HCC cells were exposed to CM from NE-treated LX-2shRNA sFRP1 (Fig. 2g). These results demonstrate that sFRP1 mediates the pro-tumoral effects of CM from NE-stimulated HSCs on malignant features of HCC cells.
On the contrary, the administration of exogenous sFRP1 promoted the migration and invasion of HCC cells in vitro (Fig. 2h; Additional file 7: Fig. S5). Concurrently, induction of EMT by sFRP1 in a dose-dependent manner in HCC cells was observed, as indicated by a decrease of E-cadherin expression and an increase of vimentin and snail expression (Fig. 2i). Further, c-Myc, cyclin D1, Nanog and β-catenin were significantly upregulated in HCC cells by sFRP1 treatment (Fig. 2i). In addition, CHIR 99021 and XAV939 influenced EMT, β-catenin activation induced by sFRP1 (Additional file 8: Fig. S6). These data suggest that exogenous sFRP1 mimicked the pro-tumoral effects of CM from NE-stimulated HSCs on malignant features of HCC cells and activation of β-catenin signaling.
Taken together, these data reveal that pro-tumoral effects of NE-stimulated HSCs on malignant characteristics of HCC cells are mediated by sFRP1, and activation of β-catenin contributes to these processes.
sFRP1 augments an autocrine feedback loop of Wnt16B/β-catenin signaling in HCC cells
As described previously, β-catenin activation may contribute to the pro-tumoral effects of sFRP1 on malignant phenotypes of HCC cells. Downregulation of β-catenin significantly suppressed the sFRP1-induced EMT, c-Myc, cyclin D1 and Nanog expression in HCC cells (Fig. 3a), suggesting that β-catenin mediates the effects of sFRP1 on HCC malignancy. To explore which Wnt family member is involved in sFRP1-activated signaling, we assessed the gene expression levels of 19 Wnt ligands in HCC cells treated with sFRP1. Wnt16B, one of the Wnt ligands, was chosen as the downstream effector based on the following reasons. As shown in Fig. S7 (Additional file 9: Fig. S7), Wnt1, Wnt3A, and Wnt16B were up-regulated in both sFRP1-treated HCC cells (MHCC97H and Huh7 cells). In addition, the relative base expression level of Wnt16B was higher than Wnt1 and Wnt3A. Also, Wnt16B mRNA expression in sFRP1-treated HCC cells was upregulated in a concentration-dependent manner. Wnt16B was remarkably elevated in sFRP1-treated HCC cells, which was confirmed by qRT-PCR and western blot (Fig. 3b). Interestingly, HCC cells treated with both sFRP1 and Wnt16B displayed more apparent EMT, evidenced by the lowest level of E-cadherin and the highest levels of N-cadherin, vimentin, and snail when compared those treated with sFRP1 or Wnt16B alone (Fig. 3c), suggesting a synergistic interaction between sFRP1 and Wnt16B. Immunofluorescence showed that sFRP1 treatment in the presence of Wnt16B further increased the accumulation of nuclear β-catenin in HCC cells (Fig. 3d). These data suggest that there exists a synergistic effect of sFRP1 and Wnt16B on augmenting β-catenin activity.
Next, we investigated how sFRP1 and Wnt16B reinforced β-catenin signaling. As shown in Fig. 3e, Wnt16B binding to FZD7 was significantly increased in the presence of sFRP1, suggesting that sFRP-1 enhances the interaction of Wnt16B with its receptor FZD7 for the induction of β-catenin activation. It has been reported that β-catenin induces Wnt-responsive genes in various types of cancer [34,35,36]. Wnt16B promoter activity in HCC cells was significantly elevated by sFRP1 (Fig. 3f). Downregulation of β-catenin significantly diminished the sFRP1-induced Wnt16B promoter activity (Fig. 3f), suggesting that sFRP-1 promotes transcriptional activation of Wnt16B through β-catenin. Because the β-catenin activity is largely mediated by the transcription factors TCF/LEF, we hypothesized that β-catenin/TCF4 binding to the Wnt16B promoter upregulates the transcriptional activation of Wnt16B based on the presence of predicted TCF4-binding motifs in the Wnt16B promoter. As shown in Fig. 3g, Wnt16B promoter activity in HCC cells was significantly elevated by TCF4. Downregulation of β-catenin significantly diminished the TCF4-induced Wnt16B promoter activity (Fig. 3g), suggesting that β-catenin promotes the transcriptional activation of Wnt16B through TCF4.
Taken together, these data indicate that sFRP1 augments an autocrine feedback loop of Wnt16B/β-catenin in HCC cells by increasing the interaction of Wnt16B with FZD7 and β-catenin/TCF4-mediated Wnt16B expression.
sFRP1 in HSCs accelerates HCC progression following chronic stress in vivo
We next investigated whether sFRP1 treatment promoted HCC progression in an in vivo model under chronic stress condition. Mice were subcutaneously injected with a cell suspension of Huh7 cells with or without LX2 cells and subjected to chronic restraint stress. The four groups of mice were all in a good general condition except two mice (one in Huh7 control group and one in Huh7 + daily stress group) died on the 15th day due to unknown reasons. The serum NE levels in the chronic restraint stress group (stress group) were significantly elevated compared with those in the control group (Fig. 4a). As shown in Fig. 4b, the growth rate of tumors was significantly accelerated in mice subjected to daily stress, particularly in the presence of LX2 cells. Similarly, regardless of tumors derived from Huh7 cells or Huh7 + LX2 cells, the size of tumors in the stress group was significantly increased when compared with the non-stress group (Fig. 4c), suggesting that stress promotes tumor progression. Notably, in mice subjected to stress condition, tumors derived from Huh7 + LX2 cells was significantly larger than tumors from Huh7 alone (Huh7 + LX2 + stress group versus Huh7 + stress group, P < 0.05; Fig. 4c), suggesting that the pro-tumor effect of stress-stimulated HSCs on HCC cells is more potent than the direct effect of stress itself on HCC cells. In Huh7/LX2 cells + daily stress group, sFRP1, N-cadherin, vimentin, snail, β-catenin c-Myc, cyclin D1, Nanog and Wnt16B expressions were significantly increased, whereas the expression of E-cadherin was markedly decreased (Fig. 4d). Consistent with the western blot results, sFRP1, N-cadherin, β-catenin, cyclin D1 were remarkably increased, whereas the expression of E-cadherin was significantly reduced in tumors in the Huh7/LX2 cells + daily stress group, as revealed by immunohistochemistry staining (Fig. 4e). To further define the role of sFRP-1 in stress-mediated HCC progression, Huh7 cell with LX-2 shRNA sFRP1 cells or LX-2shRNA NC cells were injected subcutaneously into stressed mice. Serum NE levels were similar between the two groups (Fig. 4f). After chronic restraint stress, the growth rates of tumors in the Huh7 cells+ LX-2shRNA sFRP1 group were remarkably slowed. Also, tumor sizes in the Huh7 cells+ LX-2shRNA sFRP1 group were significantly smaller than those in the Huh7+ LX-2shRNA NC group (P < 0.05) (Fig. 4h). Additionally, sFRP1, N-cadherin, vimentin, snail, β-catenin c-Myc, cyclin D1, Nanog and Wnt16B were significantly reduced, whereas E-cadherin was increased in tumors of Huh7 cells+ LX-2shRNA sFRP1 versus Huh7+ LX-2shRNA NC (Fig. 4i). According to immunohistochemical analyses, sFRP1, N-cadherin, β-catenin, cyclin D1 were significantly reduced, whereas E-cadherin was increased in tumors of Huh7 cells+ LX-2shRNA sFRP1 (Fig. 4j). These results demonstrate that chronic stress promotes sFRP1 increase in the presence of HSCs to enhance EMT, proliferation, cancer stem cell, and Wnt16B/β-catenin signaling in HCC, which is largely attenuated by knocking down sFRP1 in HSCs.
sFRP1 expression in HCC tissues
The baseline expression of sFRP1 in HSCs was significantly higher than that in the liver cell line L02 or in HCC cells (Fig. 5a, b), suggesting that the main source of sFRP1 is HSCs. To assess the clinical significance of sFRP1, we analyzed clinicopathological data in 26 patients with HCC and found that the expression of sFRP1 at both the mRNA and protein levels was remarkably higher in non-tumoral liver tissues than that in HCC tissues (Fig. 5c, d). Meanwhile, the expression of αSMA, a primary hallmark of HSC activation, was also highly expressed in non-tumoral liver tissues. Using the median expression level of α-SMA in non-tumoral tissues as a threshold, we classified the samples into two groups, a low HSC group, and a high HSC group. Compared with the low HSC group, sFRP1 was highly expressed in the high HSC group (P < 0.001, Fig. 5e), suggesting the increased sFRP1 in non-tumoral liver tissues may result from HSC production. Moreover, we grouped cases based on the median level of NE in non-tumoral tissues and found that high levels of NE in non-tumoral tissues were associated with a significant increase in sFRP1 expression (P < 0.05, Fig. 5f), suggesting that NE may increase sFRP1 in non-tumoral liver tissues. Considering the median mRNA expression level of sFRP1 in non-tumoral tissues as a threshold, we classified the cases into two groups, a low sFRP1 group, and a high sFRP1 group. In parallel, snail, cyclin D1, c-Myc, Nanog and Wnt16B levels in HCC tissues were significantly upregulated in the high sFRP1 group, whereas E-cadherin levels were clearly decreased (Fig. 5g). Additionally, a significant correlation was detected between the Vimentin/E-cadherin ratio and sFRP1 expression (P < 0.001) (Additional file 10: Fig. S8). These results suggest that NE-induced sFRP1 in non-tumoral liver tissues promotes EMT, proliferation, cancer stem cell, and Wnt16B/β-catenin signaling in HCC progression.
Associations between chronic stress and cancer progression have been studied [37, 38], and persistent SNS activation during chronic stress is known to contribute to the onset and progression of various diseases, including cancers . In this study, we present a new evidence that chronic restraint stress promotes HCC progression through the activation of HSCs by the stress hormone NE. Specifically, NE-stimulated HSCs secrete sFRP1 to enhance HCC progression by augmenting an autocrine feedback loop of Wnt16B/β-catenin signaling. Our study suggests that sFRP1 may be a new potential therapeutic target for the treatment of chronic stress-induced HCC progression.
Several physiological problems, including fear, depression, and anxiety, are often seen in patients with cancer and can chronically activate stress pathways. Continuous exposure to stress enhances the progression of cancers, and this is partly mediated by NE and epinephrine released during increased sympathetic nervous activity as part of the body’s fight-or-flight stress response . During stress, NE is locally secreted from nerve endings in various tissues and then into the blood, while epinephrine is secreted from the adrenal medulla [40,41,42]. In many types of tumors, NE, epinephrine, and activation of adrenergic receptors are involved in tumorigenesis, cancer survival, proliferation, angiogenesis, tumor progression, and metastasis through adrenergic receptor signaling-coupled intracellular molecular pathways [43, 44] or immunosuppression in the tumor microenvironment [45, 46]. Epidemiological data indicate the correlation between long-term survival of patients with cancer and β-blocker use (which antagonize NE/epinephrine receptors), suggesting a new class of potential cancer therapeutics . Catecholamines, such as NE, affect not only cancer cells that express adrenergic receptors but also stromal cells within the tumor microenvironment. Different from previous studies , which focused on adrenergic receptor signaling in tumor cells, our study examined the effects of the stress hormone NE on HSCs, a type of stromal cells rich in the fibrotic tumor environment of HCC. Electron-microscopic studies have shown that HSCs, the major fibrogenic cells in the liver, are in contact with nerve fibers in the human liver . In addition, several neuronal genes, including adrenergic receptors, are expressed in HSCs , and catecholamines are known to aggravate stress-induced liver diseases (e.g., cirrhosis) . In this study, sFRP1 was chosen as the central molecule for the following reasons. CM from NE-treated HSCs promoted the malignant behaviors of HCC cells and increased β-catenin activity, suggesting that NE-stimulated HSCs may enhance HCC malignancies by a secreted/paracrine factor, which has the role in the alteration of Wnt/β-catenin pathway. After conducting differential gene expression analysis of NE-treated versus vehicle-treated LX-2 cells, we limited our search for candidate genes related to a secreted protein whose expression can modulate Wnt/β-catenin activity. Therefore, we selected sFRP1 as a downstream effector of NE-treated HSCs for its known roles in mediating Wnt/β-catenin signaling. To the best of our knowledge, this is the first study to report that NE up-regulates sFRP1 expression in HSCs through the activation of α1A-ADR signaling and that sFRP1 signaling from NE-stimulated HSCs promotes malignant characteristics of HCC cells (EMT, parameters of proliferation-related genes, and cancer stem cell markers). This study suggests sFRP1 as a potential target for interruption of chronic stress-promoted HCC progression.
Wnt signaling has been implicated in development, homeostasis, and disease  and sFRP1, a Wnt signaling regulator, is often considered a Wnt pathway inhibitor. Loss or downregulation of sFRP1 expression plays an important role in the development and progression of various cancer, including colon cancer , lung cancer , and HCC [52, 53]. However, sFRP1 also negatively regulates tumorigenesis and cancer progression [31, 54]. For example, during the development of prostate cancer, sFRP1 secreted from tumor stroma can provide a pro-proliferative signal to adjacent prostate epithelial cells ; in gastric cancer, crosstalk of sFRP1 with TGFβ signaling promotes cell proliferation, EMT and invasion. Furthermore, high levels of sFRP1 indicate aggressiveness in some subgroups of gastric cancer and poor survival of patients . In this study, we presented the evidence that in the tumor microenvironment affected by NE, stromal HSCs within the tumor microenvironment of HCC acquire the capacity to secrete sFRP-1 and thereby promote phenotypic progression in HCC cells. Moreover, we found that sFRP1 from NE-stimulated HSCs augments an autocrine feedback loop of Wnt16B/β-catenin signaling in HCC cells by increasing the interaction of Wnt16B with the receptor FZD7 and enhancing Wnt16B expression, thereby inducing cell migration, invasion, EMT, and expression of proliferation-related markers and cancer stem cell markers to promote HCC progression. Regarding the mechanism, we found that following Wnt16B-mediated Wnt/β-catenin activation, sFRP1 further increased the nuclear translocation of β-catenin and subsequent enhancement of β-catenin/TCF4 signaling. Transcriptional activation of WNT16B was promoted by sFRP1-induced β-catenin/TCF4 signaling. Chronic restraint stress causes anxiety- and depression-like statuses in animal models. Our in vivo experiments further confirmed that sFRP1 in HSCs accelerated HCC progression in restraint-stressed mice. In accordance with the previous report that the density of α1A-ADR was increased in nontumoral liver tissues , we found that NE, α1A-ADR, α-SMA, COL1A1 (markers of HSCs activation) and sFRP1 were simultaneously over-expressed in nontumoral liver tissues, suggesting that HSCs in the peritumoral tissue may be the target of NE and the main source of sFRP1, whereas EMT, parameters of proliferation-related markers, and cancer stem cell markers, Wnt16B, and β-catenin were highly expressed in HCC tissues, suggesting that sFRP1 from HSCs in nontumoral liver tissues promotes HCC malignant characteristics. Due to a relatively small sample size of clinical HCC tissues (n = 26), the findings about the role of sFRP1 in HCC tissues need to be cautiously interpreted. Taken together, the in vitro and in vivo experiments and evaluation of clinical tumors demonstrate that NE-induced sFRP1 and subsequent initiation of Wnt16B/β-catenin signaling play significant roles in the effect of chronic stress on HCC progression, suggesting sFRP1 as a new target for blocking chronic stress-induced tumor progression.
In conclusion (Fig. 6), we demonstrate that chronic stress promotes HCC progression, in which the stress hormone NE activates HSCs to secrete sFRP1, which cooperates with a Wnt16B/β-catenin positive feedback loop. Our findings have therapeutic implications for chronic stress-accelerated HCC progression.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Hepatic stellate cells
Sympathetic nervous system
alpha-smooth muscle actin
secreted frizzled-related protein 1
Le CP, Nowell CJ, Kim-Fuchs C, Botteri E, Hiller JG, Ismail H, et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat Commun. 2016;7(undefined):10634.
Powell ND, Tarr AJ, Sheridan JF. Psychosocial stress and inflammation in cancer. Brain Behav Immun. 2013;null(undefined):S41–7.
Gjyshi A, Dash S, Cen L, Cheng CH, Zhang C, Yoder SJ, et al. Early transcriptional response of human ovarian and fallopian tube surface epithelial cells to norepinephrine. Sci Rep. 2018;8(1):8291.
Cui B, Luo Y, Tian P, Peng F, Lu J, Yang Y, et al. Stress-induced epinephrine enhances lactate dehydrogenase a and promotes breast cancer stem-like cells. J Clin Invest. 2019;129(3):1030–46.
Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, et al. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med. 2017;9(415):undefined.
Wurtman RJ. Stress and the adrenocortical control of epinephrine synthesis. Metabolism. 2002;51(null):11–4.
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939–44.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134(4):657–67.
Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology (Baltimore, Md). 2012;56(2):769–75.
Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6(undefined):425–56.
Kang N, Gores GJ, Shah VH. Hepatic stellate cells: partners in crime for liver metastases? Hepatology (Baltimore, Md). 2011;54(2):707–13.
Loréal O, Levavasseur F, Fromaget C, Gros D, Guillouzo A, Clément B. Cooperation of Ito cells and hepatocytes in the deposition of an extracellular matrix in vitro. Am J Pathol. 1993;143(2):538–44.
Coulouarn C, Corlu A, Glaise D, Guenon I, Thorgeirsson SS, Clement B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 2012;72(10):2533–42.
Wright JH, Johnson MM, Shimizu-Albergine M, Bauer RL, Hayes BJ, Surapisitchat J, et al. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. Int J Cancer. 2014;134(4):778–88.
Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21(1):35–43.
Makino Y, Hikita H, Kodama T, Shigekawa M, Yamada R, Sakamori R, et al. CTGF mediates tumor-Stroma interactions between Hepatoma cells and hepatic stellate cells to accelerate HCC progression. Cancer Res. 2018;78(17):4902–14.
Ondicova K, Mravec B. Role of nervous system in cancer aetiopathogenesis. Lancet Oncol. 2010;11(6):596–601.
Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H. Nerve-Cancer cell cross-talk: a novel promoter of tumor progression. Cancer Res. 2015;75(9):1777–81.
Oben JA, Roskams T, Yang S, Lin H, Sinelli N, Torbenson M, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut. 2004;53(3):438–45.
Sancho-Bru P, Bataller R, Colmenero J, Gasull X, Moreno M, Arroyo V, et al. Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2006;291(5):G877–84.
Bioulac-Sage P, Lafon ME, Saric J, Balabaud C. Nerves and perisinusoidal cells in human liver. J Hepatol. 1990;10(1):105–12.
vom Dahl S, Bode JG, Reinehr RM, Mönnighoff I, Kubitz R, Häussinger D. Release of osmolytes from perfused rat liver on perivascular nerve stimulation: alpha-adrenergic control of osmolyte efflux from parenchymal and nonparenchymal liver cells. Hepatology (Baltimore, Md). 1999;29(1):195–204.
Athari A, Hänecke K, Jungermann K. Prostaglandin F2 alpha and D2 release from primary Ito cell cultures after stimulation with noradrenaline and ATP but not adenosine. Hepatology (Baltimore, Md). 1994;20(null):142–8.
Liu N, Zhang XL, Liang CD, Yao DM, Liu L, Zhao DQ, et al. Dynamic changes of alpha-AR, beta1-AR and beta2-AR expression during hepatic fibrogenesis. Zhonghua Gan Zang Bing Za Zhi = Chin J Hepatol. 2009;17(9):653–6.
Kawai Y, Powell A, Arinze IJ. Adrenergic receptors in human liver plasma membranes: predominance of beta 2- and alpha 1-receptor subtypes. J Clin Endocrinol Metab. 1986;62(5):827–32.
Zhang R, Lin XH, Ma M, Chen J, Chen J, Gao DM, et al. Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition. J Transl Med. 2018;16(1):302.
Szpunar MJ, Burke KA, Dawes RP, Brown EB, Madden KS. The antidepressant desipramine and α2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure. Cancer Prev Res (Philadelphia, Pa). 2013;6(12):1262–72.
Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol. 2013;59(5):1107–17.
Mao W, Wordinger RJ, Clark AF. Focus on molecules: SFRP1. Exp Eye Res. 2010;91(5):552–3.
Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP, et al. Secreted frizzled-related protein-1 binds directly to wingless and is a biphasic modulator of Wnt signaling. J Biol Chem. 2000;275(6):4374–82.
Stojkov NJ, Baburski AZ, Bjelic MM, Sokanovic SJ, Mihajlovic AI, Drljaca DM, et al. In vivo blockade of α1-adrenergic receptors mitigates stress-disturbed cAMP and cGMP signaling in Leydig cells. Mol Hum Reprod. 2014;20(1):77–88.
Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted frizzled-related proteins in development and disease. J Cell Sci. 2008;121:737–46.
Perugorria MJ, Olaizola P, Labiano I, Esparza-Baquer A, Marzioni M, Marin JJG, et al. Wnt-β-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(2):121–36.
Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–99.
Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469–80.
Andersen BL, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum R, Courtney ME, et al. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst. 1998;90(1):30–6.
Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004;5(10):617–25.
Jansen AS, Nguyen XV, Karpitskiy V, Mettenleiter TC, Loewy AD. Central command neurons of the sympathetic nervous system: basis of the fight-or-flight response. Science (New York, NY). 1995;270(5236):644–6.
Reves JG, Karp RB, Buttner EE, Tosone S, Smith LR, Samuelson PN, et al. Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. Circulation. 1982;66(1):49–55.
Snider SR, Kuchel O. Dopamine: an important neurohormone of the sympathoadrenal system. Significance of increased peripheral dopamine release for the human stress response and hypertension. Endocr Rev. 1983;4(3):291–309.
Carbone E, Borges R, Eiden LE, García AG, Hernández-Cruz A. Chromaffin cells of the adrenal medulla: physiology, pharmacology, and disease. Comprehensive Physiology. 2019;9(4):1443–502.
Wu FQ, Fang T, Yu LX, Lv GS, Lv HW, Liang D, et al. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α. J Hepatol. 2016;65(2):314–24.
Han C, Bowen WC, Michalopoulos GK, Wu T. Alpha-1 adrenergic receptor transactivates signal transducer and activator of transcription-3 (Stat3) through activation of Src and epidermal growth factor receptor (EGFR) in hepatocytes. J Cell Physiol. 2008;216(2):486–97.
Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun. 2009;23(2):267–75.
Huan HB, Wen XD, Chen XJ, Wu L, Wu LL, Zhang L, et al. Sympathetic nervous system promotes hepatocarcinogenesis by modulating inflammation through activation of alpha1-adrenergic receptors of Kupffer cells. Brain Behav Immun. 2017;59(undefined):118–34.
Eng JW, Kokolus KM, Reed CB, Hylander BL, Ma WW, Repasky EA. A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response. Cancer Immunol Immunother. 2014;63(11):1115–28.
Liu TT, Ding TL, Ma Y, Wei W. Selective α1B- and α1D-adrenoceptor antagonists suppress noradrenaline-induced activation, proliferation and ECM secretion of rat hepatic stellate cells in vitro. Acta Pharmacol Sin. 2014;35(11):1385–92.
Chida Y, Sudo N, Kubo C. Does stress exacerbate liver diseases? J Gastroenterol Hepatol. 2006;21(null):202–8.
Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 2004;64(3):883–8.
Fukui T, Kondo M, Ito G, Maeda O, Sato N, Yoshioka H, et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene. 2005;24(41):6323–7.
Quan H, Zhou F, Nie D, Chen Q, Cai X, Shan X, et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene. 2014;33(22):2826–35.
Davaadorj M, Imura S, Saito YU, Morine Y, Ikemoto T, Yamada S, et al. Loss of SFRP1 expression is associated with poor prognosis in hepatocellular carcinoma. Anticancer Res. 2016;36(2):659–64.
Liang CJ, Wang ZW, Chang YW, Lee KC, Lin WH, Lee JL. SFRPs Are Biphasic Modulators of Wnt-Signaling-Elicited Cancer Stem Cell Properties beyond Extracellular Control. Cell Rep. 2019;28(6):1511–25.e5.
Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res. 2005;65(22):10423–30.
Qu Y, Ray PS, Li J, Cai Q, Bagaria SP, Moran C, et al. High levels of secreted frizzled-related protein 1 correlate with poor prognosis and promote tumourigenesis in gastric cancer. Eur J Cancer (Oxford, England: 1990). 2013;49(17):3718–28.
Bevilacqua M, Norbiato G, Chebat E, Baldi G, Bertora P, Regalia E, et al. Changes in alpha-1 and beta-2 adrenoceptor density in human hepatocellular carcinoma. Cancer. 1991;67(10):2543–51.
We would like to express our sincere gratitude to Prof. Jia Fan and Prof. Jian Zhou for advices and helps in the analysis of tissue.
This work was supported by the National Natural Science Foundation of China (grant nos. 81472217 and 81972715).
Ethics approval and consent to participate
The study was approved by the Zhongshan Hospital Research Ethics Committee, and written informed consent obtained from each patient. All animal experiments were approved by the Ethical Committee on Animal Experiments of Animal Care Committee of Zhongshan Hospital of Fudan University, Shanghai, China and carried out according to the Shanghai Medical Experimental Animal Care Commission Guidelines.
Consent for publication
The authors declare that they have no conflict of interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Primers used for qRT-PCR
The expression of adrenergic receptors (ADRs) in HSCs (LX2 cells, p-HSC), liver cell line L02, and HCC cells. (A) Varied expression of α1A-, α1B-, α1D-, β1-, β2-, and β3-ADR in HSCs, L02 liver cells, and HCC cells. (B) qRT-PCR analyses revealed that α1A-ADR and β2-ADR were relatively highly-expressed in LX-2 and p-HSC cells. (C) Immunofluorescent staining showed the expression of α1A-ADR in L02 and HCC cells (SMMC 7721 and HCC LM3) (magnification, × 100).
NE treatment activated HSCs. (A, B) LX-2 cells were treated with 0.1, 1, 5, and 10 μM NE for 24 h. The mRNA and protein levels of αSMA and COL1A1 were determined by qRT-PCR and western blot analyses. (C) NE treatment enhanced cell proliferation. (D) NE treatment did not increase the proliferation of HCC cells.
CM from NE-treated LX2 cells promoted the malignant phenotypes of HCC cells. (A, B) Compared with CM from NE-untreated LX2 cells, CM from NE-treated LX2 cells significantly enhanced the migration and invasion in Huh7 and MHCC 97H cells. (C, D) The expression of EMT markers (E-cadherin, N-cadherin, vimentin, snail, slug, ZEB1, and Twist), a stemness marker Nanog, and target genes of Wnt/β-catenin signaling (Axin2, c-Myc, CCND1, CD44, and LEF1) were measured by qRT-PCR in Huh7 and MHCC 97H cells co-cultured with CM from LX-2 cells versus CM from NE-treated LX-2 cells.
A total of 31 differentially expressed genes were identified in NE-treated versus vehicle-treated LX-2 cells.
sFRP1 expression in NE- treated HCC cells or LX2 cells. (A) There was no significant difference of sFRP1 expression between NE-untreated and NE- treated HCC cells. (B) Compared with other sFRP family members (sFRP2, sFRP3, sFRP4, and sFRP5), sFRP1 mRNA expression was substantially upregulated by NE in a dose-dependent manner in LX2 cells. (C) Pretreated with prazosin (10 μM) or propranolol (10 μM), LX-2 cells were treated with 10 μM NE. The expression of sFRP1 was detected by ELISA. (D) Pretreated with prazosin (10 μM) or 5-methylurapidi (5-Mu) (5 μM), LX-2 cells were treated with 10 μM NE. The protein expression of sFRP1 was detected by ELISA.
CM from NE-treated LX-2shRNA sFRP1 cells showed an attenuated promotion of malignant phenotypes of HCC cells in vitro. (A) LX-2 cells transfected with a sFRP1-shRNA lentivirus or a scramble-shRNA lentivirus. The efficiency of sFRP1 knockdown was examined in LX-2shRNA sFRP1 and LX-2shRNA NC cells. (B, C) Compared with CM from NE-treated LX-2shRNA NC, CM from NE-treated LX-2shRNA sFRP1 showed a significant decrease of invasion and migration of HCC cells in vitro, as measured by wound-healing migration assay and Matrigel invasion assay. (D, E) qRT-PCR analyses were used to detect the expression of EMT markers (E-cadherin, N-cadherin, vimentin, snail, slug, ZEB1, and Twist), stemness marker Nanog and target genes of Wnt/β-catenin signaling (Axin2, c-Myc, CCND1, CD44, and LEF1) in Huh7 and MHCC 97H cells exposed to CM from LX-2shRNA sFRP1 versus LX-2shRNA NC versus LX2. (F, G) Exogenous sFRP1 promoted the migration and invasion of HCC cells in vitro, as measured by wound-healing migration assay and Matrigel invasion assay.
CHIR 99021 and XAV939 influenced EMT and β-catenin activation induced by sFRP1.
Expression of Wnt family members in HCC cells exposed to sFRP1. (A, B) qRT-PCR analyses showed the expression levels of 19 Wnt family members in Huh7 cells exposure to 0.1, 0.5, or 1 μg/mL sFRP1 for 24 h. Fold changes represent the extent of relative mRNA change. (C) Wnt1, Wnt3A and Wnt16B were up-regulated in both sFRP1-treated HCC cells (MHCC97H and Huh7 cells). (D, E) There was a significant increase of sFRP1 in LX-2 cells treated with NE (0, 5, and 10 μM) whereas no significant change of Wnt16B was observed, as detected by qRT-PCR and western blot.
sFRP1 expression in non-tumoral tissues associated with EMT in HCC. Taken the median mRNA expression level of sFRP1 in non-tumoral tissues as a threshold, we classified the cases into two groups, a low sFRP1 group and a high sFRP1 group. Using the ratio of the mRNA expression of Vimentin and E-cadherin (Vimentin /E-cadherin) as an indicator of EMT, Vimentin /E-cadherin ratio in HCC tissues was significantly upregulated in the high sFRP1 group.
About this article
Cite this article
Lin, XH., Liu, HH., Hsu, SJ. et al. Norepinephrine-stimulated HSCs secrete sFRP1 to promote HCC progression following chronic stress via augmentation of a Wnt16B/β-catenin positive feedback loop. J Exp Clin Cancer Res 39, 64 (2020). https://doi.org/10.1186/s13046-020-01568-0
- Chronic stress
- Hepatic stellate cells
- Hepatocellular carcinoma